Vyleesi Workplace Considerations: What Premenopausal Women Need to Know

What Is Vyleesi and Why Does Timing Matter for Working Women?

Bremelanotide is a melanocortin receptor agonist approved by the FDA on June 21, 2019, specifically for premenopausal women diagnosed with acquired, generalized hypoactive sexual desire disorder (HSDD). The FDA label specifies that the drug is injected subcutaneously into the abdomen or thigh 45 minutes before anticipated sexual activity, and no more than once per 24-hour period. Unlike a daily oral medication, bremelanotide is an as-needed therapy. That single fact shapes every workplace and scheduling decision a woman makes.

Because the injection is taken before a planned intimate encounter rather than on a fixed daily schedule, most women who work standard daytime hours will inject in the evening or on weekends. That timing naturally insulates work performance from the drug's side-effect window. The challenge arises for women in shift work, those with unpredictable schedules, or those who experience side effects that extend into the following morning.

How the Drug Works

Bremelanotide activates melanocortin 3 and 4 receptors (MC3R, MC4R) in the central nervous system. Research published in the Journal of Sexual Medicine confirms this central mechanism is distinct from peripheral vascular drugs used in male sexual dysfunction. The result is a modest but statistically significant increase in sexual desire scores. In the pooled RECONNECT trials (N=1,247), women receiving bremelanotide 1.75 mg showed a mean increase of 0.5 points on the Female Sexual Function Index desire subscale versus placebo at 24 weeks [P<0.001]. [1]

The RECONNECT Trial Data in Brief

RECONNECT-1 and RECONNECT-2 were two phase 3, randomized, double-blind, placebo-controlled trials that enrolled a combined 1,247 premenopausal women with HSDD. Published in Obstetrics and Gynecology (2019), both trials used the Female Sexual Distress Scale-Desire/Arousal/Orgasm (FSDS-DAO) as a co-primary endpoint. Bremelanotide produced a statistically significant reduction in distress scores compared to placebo at 24 weeks [P<0.001]. [2] Knowing the side-effect profile from these trials is the starting point for any workplace-impact assessment.

Side Effects Most Likely to Affect Work Performance

Nausea is the dominant side effect. In the RECONNECT trials, nausea occurred in approximately 40% of bremelanotide users versus 1% of placebo users. [2] Flushing followed at roughly 20%, and injection-site bruising was reported by about 11% of participants. Transient facial flushing and warmth generally resolve within 1 to 2 hours.

For most women working a 9-to-5 schedule, an evening injection means any nausea occurs overnight and clears before morning. Women in healthcare, hospitality, or other shift roles face a different calculation.

Nausea: Duration and Management

The FDA prescribing information states nausea typically begins within 1 hour of injection and resolves within 12 hours for most patients. Antiemetic pre-treatment with ondansetron 4 mg orally 30 minutes before the injection was allowed as a rescue strategy in the RECONNECT trials and reduced nausea severity without altering bremelanotide's efficacy profile. [2] Some clinicians recommend patients trial the first dose on a Friday evening or the night before a day off to observe their personal nausea response before using the drug before a scheduled workday.

Women who find nausea persists beyond 12 hours should report this to their prescriber. Persistent or severe nausea is listed in the FDA label as a reason to consider dose discontinuation.

Blood Pressure Transient Rise

An important workplace safety point: bremelanotide produces a mean transient increase of approximately 6 mmHg systolic and 3 mmHg diastolic, peaking at about 1 hour post-injection and returning to baseline by 12 hours. Per the FDA prescribing information, women with pre-existing cardiovascular disease or uncontrolled hypertension should not use bremelanotide. [3] For a woman with well-controlled blood pressure doing sedentary office work, this transient change is unlikely to be clinically meaningful. For a woman in physically demanding employment, discussing this with a cardiologist or primary care provider before starting therapy is reasonable.

Flushing and Skin Changes

Flushing affects about 1 in 5 users and presents as warmth and redness of the face, neck, or chest. This typically resolves within 1 to 2 hours. Hyperpigmentation of the face, gums, or breasts was also reported in 1% of participants with long-term use, and is more common in women with darker skin tones. [2] The hyperpigmentation may or may not resolve after stopping the drug. Women in client-facing roles or professions where facial appearance is monitored may want to factor this into their decision-making.

Scheduling Strategies for Different Work Patterns

The as-needed nature of bremelanotide gives women meaningful control over scheduling. The FDA label places no restriction on which days of the week the injection is used, provided doses are separated by at least 24 hours.

Standard Daytime Workers

For women working Monday through Friday, 8 a.m. To 5 p.m., an injection taken at 9 p.m. Or later means the peak side-effect window (hours 1 through 4) falls entirely outside work hours. Even if nausea extends to 6 or 8 hours post-dose, the woman is asleep or at home during that period. This is the simplest and lowest-risk scheduling scenario.

Shift Workers and Night Shifts

Night-shift nurses, emergency responders, flight attendants, and similar workers face a more complex picture. If a woman works 7 p.m. To 7 a.m. Shifts, an injection taken in the early afternoon carries nausea risk during her shift. Options include:

• Reserving Vyleesi use for days off or the morning after a final night shift
• Discussing prophylactic antiemetic use with a prescriber before adopting a regular schedule
• Trialing the first two or three doses on days off before using around shift work

No specific trial data addresses shift workers using bremelanotide. This gap in the literature means clinical judgment and individual patient experience guide the approach.

Remote Workers and Home Office

Women who work from home have the most scheduling flexibility. An injection at mid-morning on a lighter workday is possible if the woman has assessed her individual nausea response and found it mild. Remote workers also face fewer concerns about visible flushing being noticed by colleagues. The blood pressure transient remains the same regardless of work setting, so the cardiovascular precautions apply equally.

Living With Vyleesi: Practical Daily Life Adjustments

Beyond the workplace, living with a bremelanotide prescription involves a set of practical habits. The FDA-approved REMS program does not apply to bremelanotide, so no special pharmacy enrollment is required. [3] However, the injection device and storage have their own demands.

Storage and Travel

Bremelanotide auto-injectors should be stored at room temperature between 68 and 77 degrees Fahrenheit (20 to 25 degrees Celsius). They do not require refrigeration, which makes travel straightforward. Women traveling by air should keep the device in a carry-on bag to avoid temperature extremes in the cargo hold. The auto-injector is a single-use prefilled device, so no reconstitution is needed.

Women attending work conferences or traveling for business can bring their auto-injectors without special documentation, though TSA screening may flag the device. Carrying the prescription label or a letter from the prescriber can resolve any airport security questions efficiently.

Privacy at Work

HSDD is a medical diagnosis. Disclosure to an employer is not legally required in the United States. Women are under no obligation to explain why they carry a medication auto-injector. The device itself resembles an epinephrine auto-injector in size and appearance. Storing it in a personal bag or locker is entirely appropriate.

Women who are concerned about colleagues noticing flushing or asking questions can prepare a simple, non-specific explanation such as a known medication side effect, without disclosing the drug name or indication.

Mental Health Dimensions of HSDD and Work

HSDD carries a significant psychological burden that may itself affect work performance. A 2018 review in the Journal of Women's Health found that women with HSDD reported significantly higher rates of anxiety, depression, and reduced quality of life compared to women without the diagnosis. [4] Effective treatment of HSDD, whether pharmacologic or through sex therapy, may therefore improve cognitive focus and emotional resilience at work indirectly, not because the drug is taken during the workday, but because distress from untreated HSDD diminishes.

The American College of Obstetricians and Gynecologists (ACOG) states in its clinical guidance that sexual dysfunction in premenopausal women warrants a multidisciplinary approach including psychological support. [5] Bremelanotide is one tool within that broader plan, not a complete solution on its own.

Interactions With Medications Commonly Used in Working-Age Women

Working-age premenopausal women frequently take medications that can interact with bremelanotide. The FDA prescribing information flags one major pharmacokinetic interaction.

Naltrexone Interaction

Bremelanotide significantly reduces the systemic exposure of naltrexone. Per the FDA label, co-administration is not recommended because bremelanotide may reduce the bioavailability of oral naltrexone by approximately 35%. [3] Women using naltrexone for alcohol use disorder or opioid dependence management should discuss this interaction with their prescriber before starting bremelanotide.

Indomethacin Interaction

Co-administration with indomethacin increased bremelanotide's area under the curve (AUC) by approximately 150% in pharmacokinetic studies cited in the FDA label. [3] Women who use indomethacin for pain management (common in working-age women with endometriosis or musculoskeletal conditions) should alert their prescriber.

Oral Contraceptives

No pharmacokinetic interaction between bremelanotide and combined oral contraceptives was identified in the RECONNECT trials, per the published primary endpoint data in Obstetrics and Gynecology. [2] Women on hormonal contraception do not need to adjust their contraceptive regimen when starting bremelanotide.

What Clinicians Say About Counseling Patients on Vyleesi at Work

The practical side-effect management gap in the prescribing information is real. The FDA label does not address shift work, air travel, or antiemetic pre-treatment protocols in detail. Clinicians filling that gap have developed informal counseling frameworks.

The Endocrine Society's position on female sexual dysfunction, published in the Journal of Clinical Endocrinology and Metabolism, emphasizes that treatment of HSDD must account for a woman's full life context, including occupational demands, rather than focusing only on pharmacodynamic endpoints. [6] That framing supports individualized scheduling discussions between prescriber and patient before the first injection is administered.

The North American Menopause Society (NAMS) clinical guidance on sexual health acknowledges bremelanotide as an option for HSDD and recommends that prescribers review lifestyle factors, including work schedules, when initiating therapy. [7]

Monitoring and Follow-Up While Using Vyleesi

Women using bremelanotide do not require routine blood tests or special monitoring beyond what their baseline care involves. Blood pressure should be measured at the initiating visit, particularly in women with any cardiovascular risk factors. A follow-up appointment at 4 to 8 weeks allows the prescriber to assess nausea frequency, blood pressure response, and efficacy.

Signs to Report Promptly

Women should contact their prescriber if they experience:

• Nausea persisting beyond 12 hours after a dose
• Facial or gum hyperpigmentation developing after several months of use
• A blood pressure reading above 160/100 mmHg in the hours following injection
• Severe injection-site reactions including prolonged bruising or induration

The RECONNECT trials recorded no serious adverse cardiovascular events in the bremelanotide arm, per the primary publication in Obstetrics and Gynecology. [2] The absence of serious cardiovascular events in a trial population does not eliminate the need for individual monitoring, particularly in women with baseline hypertension.

Stopping the Drug

Because bremelanotide is as-needed rather than daily, stopping is straightforward. There is no taper required. Per the FDA prescribing information, if a woman decides to discontinue, she simply does not administer further injections. [3] Any hyperpigmentation that developed during treatment may or may not resolve after stopping, and this should be discussed with a dermatologist if it persists.

Comparing Bremelanotide to Flibanserin (Addyi) for Lifestyle Fit

Flibanserin (Addyi), the only other FDA-approved pharmacologic treatment for HSDD in premenopausal women, is a daily oral tablet taken at bedtime. A direct comparison published in Sexual Medicine Reviews noted that flibanserin carries a black-box warning for hypotension and syncope when combined with alcohol and requires a REMS program enrollment, while bremelanotide does not require REMS. [8]

From a purely workplace standpoint, bremelanotide's as-needed dosing eliminates the adherence burden of a daily medication. Women who travel frequently, work irregular hours, or prefer not to take a daily pill may find bremelanotide's schedule more compatible with their lives. Women who want a daily medication they do not need to plan around intimate encounters may prefer flibanserin, accepting its alcohol interaction restriction.

Neither drug produces large absolute effect sizes. In RECONNECT, the number of satisfying sexual events increased by a mean of 0.5 events per month in the bremelanotide group versus placebo, per the Obstetrics and Gynecology publication. [2] That modest absolute benefit underscores why HSDD management benefits from combining pharmacotherapy with psychotherapy, relationship counseling, or both.